Stonegate Capital Partners has updated its coverage on Incannex Healthcare Inc. $(IXHL)$ for the third quarter of fiscal year 2025. The company reported a decrease in R&D expenses to $2.74M and SG&A expenses to $2.27M, resulting in a reduced net loss of $3.97M. Cash and cash equivalents increased to $6.7M due to recent financing activities. Incannex will issue ~$24.7M worth of shares to repurchase all outstanding Series A Warrants. More details can be found at newsfilecorp.com/release/167783.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.